Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations

Molecular Therapy: Oncology · Published 2026-05-28 · DOI 10.1016/j.omton.2026.201231

Free full text

Authors (2)

Giulia Escobar, Marcela V. Maus

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Escobar, G., Maus, M. (2026). Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations. Molecular Therapy: Oncology. https://doi.org/10.1016/j.omton.2026.201231

Related articles

• Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control · Molecular Therapy: Oncology · 2026 · Same journal
• Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy · Molecular Therapy: Oncology · 2026 · Same journal
• AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer · Molecular Therapy: Oncology · 2026 · Same journal
• CART-immune-related adverse events after BCMA CAR-T therapy · Molecular Therapy: Oncology · 2026 · Same journal
• Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance · Molecular Therapy: Oncology · 2026 · Same journal
• Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis · Molecular Therapy: Oncology · 2026 · Same journal
• Synergistic Cell-Cycle Repression by HDAC/EZH2 Co-Targeting in H3K27-Altered Diffuse Midline Glioma · Molecular Therapy: Oncology · 2026 · Same journal
• Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity · Molecular Therapy: Oncology · 2026 · Same journal
• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Same journal
• Strategies to prevent HNSCC by chewing gum delivery of enzymes/antimicrobials to reduce carcinogenic acetaldehyde produced by pathogenic microbes · Molecular Therapy: Oncology · 2026 · Same journal